New York, NY- June 20th, 2016- (Apple News) – Fate Therapeutics, Inc. (NASDAQ: FATE) shares have increased over 20% after the company said the FDA has granted Fast Track status to ProTmune, its drug for the reduction of the incidence and severity of acute graft-versus-host disease (GvHD). The company also announced that Phase 1/2 clinical trial of ProTmune in adult subjects with hematologic malignancies is open for patient enrollment. FATE shares are currently trading at $2.17 with over 2.5 million shares traded. Get the full story in this report. There is no cost or obligation to view the full report- https://broadstreetalerts.com/fate/
About Broad Street Alerts
We make the connection between sophisticated investors and emerging growth small-cap companies. We are an issuer of reports written by chartered financial analysts (CFA’s) and or market experts who provide an assessment of the profiled company and have pledged to provide factual up to date information in their research. They include stocks traded in the NYSE and NASDAQ exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and research report. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.
SOURCE: Broad Street Alerts